Clinical diagnostic significance of tumor markers in liver cirrhosis

V.V. Bazarny; E.N. Bessonova; N.V. Garenskih; S.Y. Malareva; N.S. Beresneva

Clinical diagnostic significance of tumor markers in liver cirrhosis

V.V. Bazarny¹, E.N. Bessonova², N.V. Garenskih³, S.Y. Malareva⁴, N.S. Beresneva⁵

research article Pages: 60-63

¹ д.м.н., профессор, кафедра клинической лабораторной диагностики и бактериологии, Уральская государственная медицинская академия (г. Екатеринбург)
² к.м.н., зав. терапевтическим отделением, Свердловская областная клиническая больница № 1 (г. Екатеринбург)
³ зав. отделением «Станция переливания крови», Свердловская областная клиническая больница № 1 (г. Екатеринбург)
⁴ врач, клинико-диагностическая лаборатория, Свердловская областная клиническая больница № 1 (г. Екатеринбург)
⁵ мл. науч. сотрудник, отдел общей патологии, ЦНИЛ Уральской государственной медицинской академии (г. Екатеринбург)

Keywords: liver cirrhosis tumor marker

Abstract

Increase of tumor markers (AFP, CA 19-9 and CA 125) levels is characteristic for liver cirrhosis, and this increase is more pronounced in decompensation stage. AFP determination can be used not only for monitoring of cirrhotic process, but also for prognosis of the speed of its progression. However, it should be mentioned that it is considered better to use a combination of tests for detection of hepatocellular carcinoma in these patients. Absence of marked deviations in CEA levels in liver cirrhosis does not allow to make definite conclusion about its value for diagnostics of hepatocellular carcinoma in patients with chronic liver diseases. In whole routine clinical application of tumor markers in patients with liver cirrhosis requires elaboration.

How to cite

Базарный В.В., Бессонова Е.Н., Гаренских Н.В., Маларева С.Я., Береснева Н.С. Клинико-диагностическое значение онкомаркеров при циррозе печени // Технологии живых систем. 2013. № 3. С. 60–63.

References

Bazarnyjj V.V., Bessonova E.N., Garenskikh N.V. Vozmozhnosti dejjstvujushhego standarta okazanija pomoshhi bolnym s cirrozom pecheni i realnye potrebnosti klinicheskojj praktiki // Klinicheskaja laboratornaja diagnostika. 2012. № 9. S. 14.
Gerok V., Bljum KH.E. Zabolevanija pecheni i zhelchevydelitelnojj sistemy. M.: «MEDpress-inform». 2009. 199 s.
Glanc S.Mediko-biologicheskaja statistika. M.: Praktika. 1998. 459 s.
Ivashkin V.T. Sovremennoe sostojanie problemy cirroza pecheni // Rossijjskijj zhurnal gastroehnterologii, gepatologii, koloproktologii. 2009. T. 19. № 1. S. 87 - 88.
Molina R., Bosch X., Auge J.M., Filella X. et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site // Tumour Biol. 2012. V. 33. № 2. P. 463 - 474.
Pissaia A. Jr., Bernard D., Scatton O., Soubrane O. et al.Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation // Transplant Proc. 2009. V. 41. № 2. P. 682 - 684.
Sturgeon C.M., Duffy M.J., Hofmann B.R., Lamerz R. et al. National Academy of Clinical BiochemistryNational Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers // Clin. Chem. 2010. V. 56. № 6. P. 1 - 48.
Tao L.Y., Cai L., He X.D., Liu W. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma // Am. Surg. 2010. V. 76. № 11. P. 1210 - 1213.

[1] Bazarnyjj V.V., Bessonova E.N., Garenskikh N.V. Vozmozhnosti dejjstvujushhego standarta okazanija pomoshhi bolnym s cirrozom pecheni i realnye potrebnosti klinicheskojj praktiki // Klinicheskaja laboratornaja diagnostika. 2012. № 9. S. 14.

[2] Gerok V., Bljum KH.E. Zabolevanija pecheni i zhelchevydelitelnojj sistemy. M.: «MEDpress-inform». 2009. 199 s.

[3] Glanc S.Mediko-biologicheskaja statistika. M.: Praktika. 1998. 459 s.

[4] Ivashkin V.T. Sovremennoe sostojanie problemy cirroza pecheni // Rossijjskijj zhurnal gastroehnterologii, gepatologii, koloproktologii. 2009. T. 19. № 1. S. 87 - 88.

[5] Molina R., Bosch X., Auge J.M., Filella X. et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site // Tumour Biol. 2012. V. 33. № 2. P. 463 - 474.

[6] Pissaia A. Jr., Bernard D., Scatton O., Soubrane O. et al.Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation // Transplant Proc. 2009. V. 41. № 2. P. 682 - 684.

[7] Sturgeon C.M., Duffy M.J., Hofmann B.R., Lamerz R. et al. National Academy of Clinical BiochemistryNational Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers // Clin. Chem. 2010. V. 56. № 6. P. 1 - 48.

[8] Tao L.Y., Cai L., He X.D., Liu W. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma // Am. Surg. 2010. V. 76. № 11. P. 1210 - 1213.